U.S. Pen Needles Market Size, Share & Trends Analysis Report By Product (Standard & Safety Pen Needles), By Needle Length (4mm, 5mm, 10mm, 12mm), By Therapy (Insulin, Glucagon-like-Peptide-1), And Segment) - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The U.S. pen needles market size was valued at USD 992.80 million in 2023 and is projected to surpass around USD 2,598.57 million by 2033, registering a CAGR of 10.1% over the forecast period of 2024 to 2033. 

Key Takeaways:

• Insulin dominated the market with the highest revenue market share in 2023 of 84.11% and is also expected to grow at the fastest CAGR over the forecast period.
• Glucagon-like-Peptide-1 (GLP-1) is expected to witness lucrative growth during the forecast period.
• Standard pen needles dominated the market with the largest revenue share in 2023.
• Safety pen needles are expected to grow at the fastest CAGR of 11.9% during the forecast period.
• 5mm dominated the market and accounted for the largest revenue market share of over 20.19% in 2023.
• 4mm is anticipated to witness the fastest CAGR during the forecast period.

U.S. Pen Needles Market Growth

The rising prevalence of chronic diseases, advancement in needle technology, awareness and adoption of injector pens, and the rise in consumer awareness, patient comfort, and accessibility collectively contribute to the growth of the market. Furthermore, the escalating incidence of diabetes is driving an increased need for pen needles. The International Diabetes Federation (IDF) projects that by 2040, the number of people with diabetes will reach 642 million. Given the expanding diabetic population, the target market is anticipated to experience significant growth during the projected period.

The U.S. accounted for over 24.9% of the global pen needles market in 2023. The rise in chronic diseases, especially diabetes, necessitates the frequent and accurate administration of medications, thereby increasing the demand for pen needles. Pen injectors are frequently utilized by individuals with diabetes to administer insulin or other medications. People with obesity are particularly prone to diabetes, and insulin pens provide a convenient and rapid method for drug injection. The demand for pen needles is increasing in line with the growing need for insulin pens among diabetic patients. These devices, when used with insulin pens, assist in accurately delivering the drug dosage to the patient.

Innovations in needle technology, such as ultra-thin and painless needles, are enhancing convenience and accessibility, further driving the market. Moreover, growing awareness and adoption of injector pens for self-administration of medications are also boosting the demand. These pens offer benefits like ease of use, accurate dosing, and reduced risk of needlestick injuries. A focus on patient comfort and accessibility in healthcare has led to the development of innovative pen needle designs that improve the patient experience by reducing injection pain, thereby propelling market growth. In addition, continuous research and development have resulted in technological advancements like non-needle injection systems and needle-free microneedle arrays. These innovations promise to further reduce injection pain and enhance patient comfort, contributing to market expansion.

U.S. Pen Needles Market Report Scope

U.S. Pen Needles Market ByTherapy Insights

Insulin dominated the market with the highest revenue market share in 2023 of 84.11% and is also expected to grow at the fastest CAGR over the forecast period. Therapies are increasingly being shifted to home settings due to the rise of home healthcare and self-administration, leading to a surge in demand for insulin pen needles. These needles provide a convenient and less intrusive method for insulin injection. The growing prevalence of biosimilar drugs necessitates the need for compatible insulin pen needles, thereby driving market growth. Favourable reimbursement scenarios are fuelling the demand for this therapy. Moreover, awareness of self-administered insulin therapy growing among diabetes patients is also expected to boost the segment’s growth.

Glucagon-like-Peptide-1 (GLP-1) is expected to witness lucrative growth during the forecast period. This growth is primarily driven by the rising inclination towards GLP-1 therapies, increasing patient demand, the efficacy of GLP-1 receptor agonists in diabetes management, market trends that prioritize patient comfort, and ongoing technological enhancements in pen needle design specifically for GLP-1 medications. These elements collectively contribute to the rise of the GLP-1 segment in the market, indicating a significant increase in the demand for pen needles that are compatible with GLP-1-based therapies. The FDA has approved Lilly’s MounjaroTM, the first GIP and GLP-1 receptor agonist for type 2 diabetes management. GLP-1 therapy, which reduces blood glucose levels, is expected to grow significantly.

U.S. Pen Needles Market By Product Insights

Standard pen needles dominated the market with the largest revenue share in 2023. This was largely due to the rise in frequent use of standard pen needles by diabetic patients who require larger doses. These needles are commonly used by individuals with dexterity issues. However, they are not the preferred choice due to the significant risk of needlestick injuries, which compromises their safe use. As a result, their demand is expected to decrease in the future. The growth of this segment is supported by the increasing diabetic population and the heightened awareness about the use of insulin pens. According to recent data, 37.3 million Americans or 11.3% of U.S. population are affected with diabetes.

Safety pen needles are expected to grow at the fastest CAGR of 11.9% during the forecast period due. This growth is attributed to ongoing technological advancements in this area. Safety pen needles (SPNs) help reduce the occurrence of needlestick injuries among patients and are currently viewed as the better mode of medication. For example, the National Library of Medicine reports that most needlestick injuries (NSIs) are due to defective needles. Safety pen needles are equipped with a built-in sharps injury prevention function (SIPF) that aids in preventing such injuries before, during, and after use.

U.S. Pen Needles Market By Needle Length Insights

5mm dominated the market and accounted for the largest revenue market share of over 20.19% in 2023. Pen needles with a length of 5mm offer numerous benefits to patients. These needles, which are shorter and thinner, are appropriate for most people, making insulin administration more comfortable and straightforward. They are especially beneficial for those who have difficulty with hand strength, as these needles ensure the effective delivery of the full insulin dose. Moreover, these shorter 5mm needles facilitate the delivery of insulin just beneath the skin, eliminating the need for skin pinching during injections and reducing the risk of muscle tissue injections. Research has demonstrated that even in obese patients, needles shorter than 8mm are just as effective while reducing the chance of intramuscular injections.

4mm is anticipated to witness the fastest CAGR during the forecast period owing to its short length. Patients are progressively opting for the shortest and thinnest needles due to the enhanced comfort they provide compared to traditional injections. These needles, with their short length, can effortlessly access the patient’s subcutaneous tissue. Recent research indicates that these short-length needles are equally effective as the longer ones. For individuals with trypanophobia, these needles are a simple solution. Utilizing needles that are 4mm or smaller can mitigate the side effects of intramuscular injections and prevent inconsistent dosages, thus fulling the growth of this segment.

U.S. Pen Needles Market Recent Developments

• In September 2022, Terumo India, a subsidiary of Terumo Corporation, has publicized the introduction of FineGlide, a Sterile Pen Needle. This product is intended for patients who need to administer insulin injections or other self-medication regularly.
• In May 2022, Novo Nordisk A/S discontinued the production of NovoTwist 32G 5 mm needles. However, Novo Nordisk provides a variety of other needle choices, such as the NovoFine Plus, which is their smallest and slimmest needle, engineered to enhance the comfort of injections.
• In February 2021, UltiMed Inc. announced their release of Ulticare safety pens that comes in two sizes, 5mm 30G and 8mm 30G. This technology hides the needle both before and after its use, aiding in the prevention of unintentional needle stick injuries. This innovation was made for safer injection and better customer experience.

Key U.S. Pen Needles Company Insights

Leading companies in the U.S. pen needles market are employing various strategic measures such as partnerships, expansion of products and services, mergers and acquisitions, and R&D investments to gain a competitive edge through advanced applications. The market is dominated by key players like Novo Nordisk A/S, Becton, Dickinson and Company, TERUMO CORPORATION, Owen Mumford Ltd., Ypsomed, B. Braun Melsungen AG, HTL-STREFA, UltiMed, Inc., Allison Medical, Inc., and Artsana S.p.a. These major firms are undertaking initiatives like mergers and acquisitions, new product developments, and geographical expansions to meet the growing patient needs. For instance, in February 2023, Montmed Inc. announced the issuance of a second U.S. patent for the Sitesmart Pen Needles.

U.S. Pen Needles Market Top Key Companies:

• Novo Nordisk A/S
• Becton
• Dickinson and Company
• Terumo Corp.
• Owen Mumford Ltd.
• Ypsomed
• B. Braun Melsungen AG
• HTL-STREFA
• UltiMed, Inc.
• Allison Medical, Inc.
• Artsana S.p.A.

U.S. Pen Needles Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Pen Needles market.

By Product 

• Standard Pen Needles
• Safety Pen Needles

By Needle Length 

• 4 mm
• 5 mm
• 6 mm
• 8 mm
• 10 mm
• 12 mm

By Therapy 

• Insulin
• Glucagon-like-Peptide-1 (GLP-1)
• Growth Hormone